Answers are grounded in this paper and cite their sources.
BACKGROUND: The combination of 2 broadly neutralizing antibodies (bNAbs), teropavimab and zinlirvimab, plus the capsid inhibitor lenacapavir, is a potential twice-yearly regimen for HIV-1 treatment. The level of bNAb susceptibility to maintain virologic suppression is unknown; therefore, we evaluated this combination in participants meeting stringent viral sensitivity criteria to only 1 of the 2 bNAbs. METHODS: This was a pilot study within a proof-of-concept phase 1b study. RESULTS: No serious treatment-emergent adverse events occurred and 8 of 10 participants remained virologically suppressed at week 26. CONCLUSIONS: More inclusive bNAb susceptibility criteria may be appropriate for future studies of this combination treatment. Clinical Trials Registration. NCT04811040.
No takes yet. Share an insight, caveat, or question.
Eron et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: